MedBulletinsAura Celeste
GI

Monthly gastroenterology bulletin — September 28, 2026

🎧 Listen to this issueAudio newscast · 5:24 min

Colleagues: this issue covers what was published, presented or approved between August 28 and September 28, 2026. It was a month with more regulatory and industry signals than phase 3 trials published in journals; in East Asia, Russia, the Middle East and Turkey we found no verifiable primary publications from the period, so we did not pad. Twelve items, each with a critical reading and a link to the primary source.

Hepatology

1. Baveno VIII: portal hypertension management turns toward preventing decompensation

[Guideline] [Europe, Baveno Cooperation / EASL]
The Baveno VIII consensus (272 statements, more than 80 experts, 80% agreement threshold) was published in the Journal of Hepatology and disseminated in September. Concrete changes: clinically significant portal hypertension (CSPH) is ruled out with liver stiffness ≤15 kPa plus platelets ≥150 × 10⁹/L; it is ruled in with stiffness ≥25 kPa (viral, alcohol or non-obese MASLD), spleen stiffness >55 kPa or a ≥75% probability in validated models; carvedilol is recommended to prevent decompensation in compensated cirrhosis with CSPH (for example, probability ≥75%), and "recompensation" is defined (no ascites, encephalopathy or rebleeding for more than six months, with Child A). It adds a pediatric chapter for the first time and consolidates pre-emptive TIPS within 72 hours (ideally 24) of high-risk variceal bleeding.
Why it matters: this is the reference guideline for the next decade, but many of the new statements (recompensation, pediatrics, vascular liver disease) rest on low-level evidence and expert opinion; in the Dominican Republic the bottleneck remains timely access to elastography and TIPS.
https://www.journal-of-hepatology.eu/article/S0168-8278(26)02778-9/fulltext
https://news.gastro.org/issues/2026/september-2026/baveno-viii-shifts-portal-hypertension-care-toward-prevention/

2. Elafibranor in primary biliary cholangitis: two years of controlled data from ELATIVE

[Clinical trial] [Multinational] [Outside the period: August 27]
The Journal of Hepatology published online (August 27) the two-year results of the phase 3 ELATIVE trial (161 patients with PBC randomized 2:1 to elafibranor 80 mg or placebo). In the double-blind phase, biochemical response at week 104 was 64.3% (18/28) with elafibranor and alkaline phosphatase normalization 10.7% (3/28); no placebo-treated patient achieved either outcome. Among patients with moderate-to-severe pruritus at baseline, the worst-itch score fell 4.1 points with elafibranor vs +0.3 with placebo. In the open-label extension, 58.8% (47/80) of patients continuing elafibranor had a biochemical response at week 104; the authors report no unexpected safety findings with up to 3.5 years of exposure.
Why it matters: it supports the durability of the biochemical and pruritus effect, but with very few patients at the late cutoff (28 on elafibranor at week 104), a pruritus finding limited to a subgroup and no hard clinical outcomes; access remains limited in our region.
https://doi.org/10.1016/j.jhep.2026.08.016
https://pubmed.ncbi.nlm.nih.gov/42660235/

3. Alcohol and cardiometabolic factors: absolute 10-year cirrhosis risk in 354,624 Danes

[Publication] [Denmark] [Outside the period: August 24]
Population cohort (Danish National Health Surveys 2010–2017; 3.3 million person-years; 1,211 incident cirrhoses). Absolute 10-year risk was 0.14% at 1–7 drinks per week, 0.29% at 8–14, 0.68% at 15–28, 2.0% at 29–42 and 4.6% above 42. Obesity (BMI ≥30), diabetes, hypertension and smoking were each associated with a two- to threefold higher risk; obesity, diabetes and hypertension increased risk at 1–28 drinks per week but not above 28, whereas smoking increased it at all levels of intake. Population attributable fractions: alcohol 59.9%, hypertension 29.3%, smoking 21.2%, obesity 13.8%, diabetes 9.0%.
Why it matters: it provides absolute figures useful in the clinic and reinforces that alcohol dominates risk in heavy drinkers even in the MASLD era; it is observational and intake comes from a self-reported survey. Published online August 24, at the edge of the permitted window.
https://doi.org/10.1016/j.jhep.2026.08.017
https://pubmed.ncbi.nlm.nih.gov/42637052/

4. Spleen stiffness ≤40 kPa rules out high-risk varices in chronic portal vein thrombosis without cirrhosis

[Publication] [Multinational, 16 VALDIG centres]
Retrospective multicentre study (16 VALDIG centres; derivation cohort n = 159, 43% with high-risk varices; validation n = 187, 32%) published online September 1 in the Journal of Hepatology. With spleen stiffness by transient elastography ≤40 kPa, sensitivity was 97% and negative predictive value 97% in derivation (96% in validation), sparing 41–43% of endoscopies with 3–5% of high-risk varices missed.
Why it matters: it extends the Baveno logic to a population without non-invasive criteria, but it is retrospective and accepted endoscopies up to two years before or after the measurement; prospective validation is needed before omitting endoscopy.
https://doi.org/10.1016/j.jhep.2026.08.026
https://pubmed.ncbi.nlm.nih.gov/42679862/

Inflammatory bowel disease and the intestine

5. Anti-IL-15 antibody (TEV '408) protects the duodenal mucosa during gluten challenge in celiac disease

[Industry] [Israel, Teva]
On September 2 Teva reported a randomized, placebo-controlled phase 2a trial (n = 50): a single subcutaneous dose followed by a six-week gluten challenge. Change in villus height-to-crypt depth ratio at week 8: −0.43 with TEV '408 vs −0.88 with placebo (difference 0.45; 95% CI 0.06–0.84; p < 0.05); intraepithelial lymphocyte density: +0.37 vs +27.6 (difference −27.2; 95% CI −39.7 to −14.8). No safety signals reported.
Why it matters: this is a favorable histological signal for an anti-IL-15 in celiac disease, but the data are preliminary press-release results, not peer reviewed, with a small sample and a surrogate endpoint; it does not change practice (the gluten-free diet remains the treatment).
https://www.globenewswire.com/news-release/2026/09/02/3354990/0/en/teva-announces-positive-topline-results-from-phase-2a-study-in-celiac-disease-for-its-anti-il-15-antibody-further-validating-its-pipeline-in-a-product-potential.html

6. SPY003 (long-acting anti-IL-23) in ulcerative colitis: SKYLINE Part A

[Industry] [United States, Spyre Therapeutics]
On September 8 Spyre presented the open-label, uncontrolled Part A of its phase 2 trial (n = 44; 41% previously exposed to advanced therapies). At week 12 the Robarts histological index fell 10.0 points (p < 0.0001), with 20% clinical remission, 30% endoscopic improvement and a single drug-related adverse event (grade 1 pruritus).
Why it matters: it completes proof of concept for the three components the company plans to combine (anti-α4β7, anti-TL1A, anti-IL-23), but without placebo or blinding these figures cannot be compared with the class; the randomized Part B with combinations is not due until 2027.
https://www.globenewswire.com/news-release/2026/09/08/3357613/0/en/spyre-announces-potential-best-in-class-spy003-anti-il-23-part-a-induction-results-from-skyline-trial-completing-proof-of-concept-for-all-three-components-of-its-ibd-combinations.html

7. Glepaglutide (GLP-2 analog) receives a positive CHMP opinion for short bowel syndrome

[EMA regulatory] [Denmark / European Union]
At its September 14–17 meeting the CHMP recommended approval of Zeydovio (glepaglutide, two subcutaneous injections per week) for adults with short bowel syndrome. In the phase 3 EASE-1 trial (n = 106, dependent on parenteral support ≥3 days/week), the twice-weekly regimen reduced weekly parenteral volume by 5.13 L vs 2.85 L with placebo (p = 0.0039); ≥20% response: 65.7% vs 38.9%; nine glepaglutide-treated patients (five on the twice-weekly regimen) reached enteral autonomy vs none on placebo.
Why it matters: according to Zealand, it would be the first major advance in Europe in more than a decade for a small population with an enormous care burden; the European Commission decision is expected within about two months and U.S. registration still depends on the EASE-5 trial.
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2026
https://www.globenewswire.com/news-release/2026/09/18/3364558/0/en/zealand-pharma-receives-positive-chmp-opinion-for-zeydovio-glepaglutide-for-the-treatment-of-short-bowel-syndrome.html

Endoscopy and digestive oncology

8. BioNTech and Genentech terminate the phase 2 trial of the mRNA vaccine autogene cevumeran in resected colorectal cancer

[Industry] [Germany] [Outside the period: August 28]
On August 28 BioNTech announced termination of the BNT122-01 trial (NCT04486378), which compared individualized mRNA immunotherapy as monotherapy against watchful waiting in resected, ctDNA-positive high-risk stage II or stage III colorectal cancer. After crossing the futility boundary in October 2025, the data monitoring board now identified a numerical overall survival imbalance between arms and recommended stopping; no figures have been released. No new safety signals.
Why it matters: it is a serious brake on mRNA vaccines as monotherapy in "cold" tumors such as colorectal cancer; the absence of numbers means waiting for the full publication, and the pancreatic cancer program (with chemotherapy and immunotherapy) continues.
https://www.biontech.com/int/en/home/mediaroom/news/statements/2026/08/BioNTech-Provides-Update-on-Phase-2-Clinical-Trial-of-Autogene-Cevumeran-in-Resected-Colorectal-Cancer.html

9. Ivonescimab plus chemotherapy improves overall survival in advanced biliary tract cancer (HARMONi-GI1)

[Industry] [China, Akeso]
Akeso announced on September 21 that its randomized, double-blind phase 3 HARMONi-GI1 trial (ivonescimab, a PD-1/VEGF bispecific, plus chemotherapy vs durvalumab plus chemotherapy in first line) met its overall survival endpoint. Full data will be presented as a late-breaking abstract (LBA8) in the presidential symposium of ESMO 2026 on October 25 in Madrid.
Why it matters: the comparator is an active immunotherapy regimen (durvalumab), but until hazard ratio, n and population are seen it cannot be judged; the sponsor has every incentive and Chinese results with ivonescimab have not always replicated in Western populations.
https://www.prnewswire.com/news-releases/ivonescimab-first-line-biliary-tract-cancer-phase-iii-overall-survival-data-selected-as-esmo-late-breaking-abstract-nearly-30-akeso-studies-to-be-presented-at-esmo-2026-302885329.html

Pancreas, esophagus and stomach

10. FDA approves daraxonrasib, a RAS-family inhibitor, for metastatic pancreatic cancer

[FDA regulatory] [United States, Revolution Medicines] [Outside the period: August 26]
On August 26 the FDA approved daraxonrasib (Rasonque, 300 mg orally once daily) for adults with metastatic pancreatic adenocarcinoma after at least one systemic line or who are not candidates for multiagent therapy. Basis: the RASolute 302 trial (n = 500, randomized, open-label, vs physician's choice chemotherapy). Median overall survival 13.2 vs 6.7 months (HR 0.40; 95% CI 0.30–0.53); progression-free survival 7.2 vs 3.6 months (HR 0.49); objective response 30% vs 11%. Warnings: dermatologic toxicity, stomatitis, diarrhea, gastrointestinal perforation, pneumonitis and embryo-fetal toxicity. Approval came six and a half months ahead of the goal date.
Why it matters: it is the largest second-line advance in pancreatic cancer in decades and directly concerns the gastroenterologist who diagnoses and follows these patients; the open-label design and the lack of published RAS G12 subgroup figures are limitations, and price and availability in Latin America are unknown.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daraxonrasib-metastatic-pancreatic-adenocarcinoma

11. Very hot drinks and esophageal squamous cell carcinoma: nearly one million British adults

[Publication] [United Kingdom, Oxford Population Health]
Cancer Research UK released on September 9 an analysis of UK Biobank and the Million Women Study (about 980,000 adults, more than ten years of follow-up): those who drink their beverages "hot" had nearly twice the risk of esophageal squamous cell carcinoma compared with "warm" drinkers, and "very hot" drinkers three times the risk. Risk was linked to drink temperature, not to tea or coffee consumption itself.
Why it matters: it confirms in a Western population what IARC already classified as "probably carcinogenic" above 65 °C, with the limitation that temperature was self-reported and no hazard ratios or confidence intervals were published in the release; the practical message is simple and applicable in any clinic.
https://news.cancerresearchuk.org/2026/09/09/link-between-hot-drinks-and-type-of-oesophageal-cancer-in-the-uk/

Cross-cutting

12. XXXIV Dominican Congress of Gastroenterology (SODOGASTRO), Miches, September 17–20

[Meeting] [Dominican Republic]
The annual congress of the Dominican Society of Gastroenterology was held at the Miches Convention Center under the motto "From knowledge to action", dedicated to Dr. Luis Pérez Méndez. The program included vonoprazan, third-space endoscopy, standardized upper-endoscopy reporting (STAR Project), IBD epidemiology in the country, Rome V criteria, artificial intelligence in endoscopy and a hepatology module (MASLD, hepatitis B, cirrhosis, transplantation).
Why it matters: it is the local reference for what is being adopted in the country; we found no abstracts or registry data published from the congress, so its value this month is agenda and professional networking.
https://diariosalud.do/xxxiv-congreso-dominicano-gastroenterologia-programa

Note of the month: obefazimod (ABTECT, maintenance) circulated again in the specialty press in September, but the data are those of the June 1 press release and there is no new publication, so it is not included. The September CHMP also recommended a tofacitinib generic (Inijaq) with an ulcerative colitis indication and an extension of indication for filgotinib (Jyseleca) whose wording the CHMP highlights do not specify.

Upcoming meetings and dates

  • ACG 2026 Annual Scientific Meeting: October 9–14, Nashville (Music City Center).
  • UEG Week 2026: October 17–20, Barcelona (Fira Gran Via) and online.
  • ESMO Congress 2026: October 23–27, Madrid; HARMONi-GI1 data are presented October 25.
  • The Liver Meeting 2026 (AASLD): November 5–9, Denver.

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.